Our Pipeline
Targeting Mast Cell and Inflammasome Biology to Treat Immune Mediated Inflammatory Disorders
We believe our pipeline holds the potential to transform the lives of millions of patients suffering from IMIDs. Explore our current and future endeavors:
We believe this oral, small molecule inhibitor of chymase has the potential to revolutionize the treatment of conditions like chronic urticaria (CU), prurigo nodularis (PN), and atopic dermatitis (AD). We are on track to initiate a Phase 2a trial for CU, subject to receiving regulatory approvals.
Our novel oral small molecule multi-inflammasome inhibitor targets apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC). We believe this innovative approach could address the underlying immunopathology of chronic inflammation across various IMIDs.
Using InveniAI’s AlphaMeld Platform, powered by AI and ML technology, and our team of developers we continue to explore select additional small molecule product candidates, which we plan to either in-license or design in-house.
We believe in the potential of our product candidates to provide well-tolerated and effective solutions for patients. Our commitment to rigorous research and development drives us to push the boundaries of IMID treatment.
We believe our pipeline holds the potential to transform the lives of millions of patients suffering from IMIDs. Explore our current and future endeavors:
INVA8001: We believe this oral, small molecule inhibitor of chymase has the potential to revolutionize the treatment of conditions like atopic dermatitis (AD) and chronic urticaria (CU). We are on track to initiate a Phase 2b trial for AD and a Phase 1b trial for ISM, subject to receiving regulatory approvals.
INVA8003: Our novel oral small molecule multi-inflammasome inhibitor targets apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC). We believe this innovative approach could address the underlying immunopathology of chronic inflammation across various IMIDs.
DISCOVERY PIPELINE: Using InveniAI’s AlphaMeld Platform, powered by AI and ML technology, and our team of developers we continue to explore select additional small molecule product candidates, which we plan to either in-license or design in-house.
We believe in the potential of our product candidates to provide well-tolerated and effective solutions for patients. Our commitment to rigorous research and development drives us to push the boundaries of IMID treatment.
INVA8001
We believe this oral, small molecule inhibitor of chymase has the potential to revolutionize the treatment of conditions like atopic dermatitis (AD) and chronic urticaria (CU). We are on track to initiate a Phase 2b trial for AD and a Phase 1b trial for ISM, subject to receiving regulatory approvals.
INVA8002
INVA8002 is a novel orally delivered colon-targeted formulation of a small molecule inhibitor of a 5-HT3 receptor for the treatment of moderate to severe Ulcerative Colitis (UC), a common form of Inflammatory Bowel Disease (IBD).
INVA8003
INVA8003 is a first-in-class pan- inflammasome inhibitor targeting ASC protein oligomerization, which disrupts the inflammasome assembly of NLR/Ps with a broad anti-inflammatory impact and potential applications across a wide range of inflammatory GI disorders.
